Author:
Houdou Lucie,Thibault Constance
Subject
Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,Hematology,General Medicine
Reference5 articles.
1. Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide;Fizazi;N Engl J Med,2020
2. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer;Smith;N Engl J Med,2022
3. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2×2 factorial design;Fizazi;Lancet Lond Engl,2022
4. French AFU Cancer Committee Guidelines – update 2022–2024: prostate cancer – management of metastatic disease and castration resistance;Ploussard;Progres Urol,2022
5. Androgen receptor signaling inhibitors in addition to docetaxel with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis | Elsevier enhanced reader [Internet]. [cité 3 févr 2023]. Disponible sur : https://reader.elsevier.com/reader/sd/pii/S0302283822025519?token=67A47A472FFCA89C6FC014CFEC45A96386B51A03F562DB42C16F2B594284A6B406385F51B9370863E72BE19018053F20&originRegion=eu-west-1&originCreation=20230203162840.